[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].Yukio Inuyama, T Taguchi, Akikatu KATAURA et al.|PubMed|1999Cited by 21
Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo).Heidi D. Klepin, Arti Hurria, CP Gross et al.|Journal of Clinical Oncology|2011Cited by 2
Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes.Ajeet Gajra, Arti Hurria, Molly Hardt et al.|Journal of Clinical Oncology|2011Cited by 1